ArticleCancers2020
Single-Cell NGS-Based Analysis of Copy Number Alterations Reveals New Insights in Circulating Tumor Cells Persistence in Early-Stage Breast Cancer.
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2- Metastatic Breast Cancer.Cancer science · 2026Article
- Automated Analysis of Liquid Biopsy Using Deep Learning: Detecting Circulating Tumor Cells and Cancer-Associated Fibroblasts.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Gastroesophageal circulating tumor cell crosstalk with peripheral immune system guides CTC survival and proliferation.Cell death & disease · 2025Article
- Knowledge-map and research trends of circulating tumor cells in breast cancer: a scientometric analysis.Discover oncology · 2024Article
- Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer.Scientific reports · 2024Article
- Evaluating circulating tumour cell enrichment techniques to establish an appropriate method for clinical application in glioblastomas.Frontiers in neurology · 2024Article
- Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring.Oncology research · 2023Review
- Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.Therapeutic advances in medical oncology · 2023Review
- Review
- Shallow WGS of individual CTCs identifies actionable targets for informing treatment decisions in metastatic breast cancer.British journal of cancer · 2022Article
- Article
- Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers.International journal of molecular sciences · 2022Review
- Article
- Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer.Scientific reports · 2022Article
- Circulating tumor cells in the early detection of human cancers.International journal of biological sciences · 2022Review
- From phenotypical investigation to RNA-sequencing for gene expression analysis: A workflow for single and pooled rare cells.Frontiers in genetics · 2022Article
- Article
- Circulating Tumor Cells as a Tool to Untangle the Breast Cancer Heterogeneity Issue.Biomedicines · 2021Review
- Metastasis Prevention: Focus on Metastatic Circulating Tumor Cells.Molecular diagnosis & therapy · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating tumor cells (CTCs) are a rare population of cells representing a key player in the metastatic cascade. They are recognized as a validated tool for the identification of patients with a higher risk of relapse, including those diagnosed with breast cancer (BC). However, CTCs are characterized by high levels of heterogeneity that also involve copy number alterations (CNAs), structural variations associated with gene dosage changes. In this study, single CTCs were isolated from the peripheral blood of 11 early-stage BC patients at different time points. A label-free enrichment of CTCs was performed using OncoQuick, and single CTCs were isolated using DEPArray. Libraries were prepared from single CTCs and DNA extracted from matched tumor tissues for a whole-genome low-coverage next-generation sequencing (NGS) analysis using the Ion Torrent S5 System. The analysis of the CNA burden highlighted that CTCs had different degrees of aberration based on the time point and subtype. CTCs were found even six months after surgery and shared CNAs with matched tumor tissue. Tumor-associated CNAs that were recurrent in CTCs were patient-specific, and some alterations involved regions associated with BC and survival (i.e., gains at 1q21-23 and 5p15.33). The enrichment analysis emphasized the involvement of aberrations of terms, associated in particular with interferon (IFN) signaling. Collectively, our findings reveal that these aberrations may contribute to understanding the molecular mechanisms involving CTC-related processes and their survival ability in occult niches, supporting the goal of exploiting their application in patients' surveillance and follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.